Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.42 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.42 |
| ▸ | EIF4H | Q15056 | 2/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5846673 | 0.84 | MAPT (0.68) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL2268884 | 0.80 | MAPT (0.75) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL2481251 | 0.78 | TTR (0.59) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL4923617 | 0.76 | MAPT (0.66) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL9150772 | 0.75 | MAPT (0.68) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL2241739 | 0.74 | CA12 (0.54) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL7465791 | 0.74 | MAPT (0.56) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL2525113 | 0.73 | MAPT (0.55) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL6995480 | 0.73 | S100A4 (0.53) | MAPTALDH1A1MEN1KMT2APABPC1 | |
| SCHEMBL9354610 | 0.72 | MAPT (0.54) | MAPTCA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076348-B2 | Acylguanidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-12-13 | — | — | US | disclosed |
| EP-1923387-B1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2011-10-19 | — | — | EP | disclosed |
| US-20100168096-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-1923387-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168096-A1 | ACYLGUANIDINE DERIVATIVE OR SALT THEREOF | HTR2B, HTR7, HTR3B | MAPT 4231/4885CA12 2807/4885CA1 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.